Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular and intranigral delivery

Neuroscience

Volumn 78, Issue 1, 1997, Pages 61-72

  Lapchak, P A ^a   Miller, P J ^a   Collins, F ^a   Jiao, S ^a  

^a AMGEN INC   (United States)

Author keywords

dynorphin; enkephalin; GDNF; Parkinson's disease; substance P; tyrosine hydroxylase

Indexed keywords

DYNORPHIN A; ENKEPHALIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; SUBSTANCE P; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

EID: 0030950227     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)83045-X     Document Type: Article

References (41)

1. Angulo J. A., Cadet J. L. and Woolley C. S. (1990) Effect of chronic typical and atypical neuroleptic treatment on proenkephalin mRNA levels in the striatum and nucleus accumbens of the rat. J. Neurochem. 54, 1889-1894.
2. Berretta S., Robertson H. A. and Graybiel A. M. (1993) Neurochemically specialized projection neurons of the striatum respond differentially to psychomotor stimulants. Prog. Brain Res. 99, 201-205.
3. Besson M. J., Graybiel A. M. and Quinn B. (1990) Co-expression of neuropeptides in the cat's striatum: an immunohistochemical study of substance P, dynorphin B and enkephalin. Neuroscience 39, 33-58.
4. Bowenkamp K. E., Hoffman A. F., Gerhardt G. A., Henry M. A., Biddle P. T., Hoffer B. J. and Granholm A. C. E. (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. comp. Neurol. 355, 479-489.
5. Bowenkamp K. E., David D., Lapchak P. A., Henry M. A., Granholm A. C., Hoffer B. J. and and Mahalik T. J. (1996) 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. Expl Brain Res. 11, 1-7.
6. Drago J., Gerfen C. R., Lachowitz J. E., Steiner H., Hollon T. R., Love P. E., Ooi G. T., Grinberg A., Lee E. J., Huang S. P., Bartlett P. F., Jose P. A., Sibley D. R. and Westphal H. (1994) Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. natn. Acad. Sci. U.S.A. 91, 12564-12568.
7. Engber T. M., Susel Z., Kuo S., Gerfen C. R. and Chase T. N. (1991) Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552, 113-118.
8. Fernandez A., de Caballos M. L., Jenner P. and Marsden C. D. (1992) Striatal neuropeptide levels in Parkinson's disease patients. Neurosci. Lett. 145, 171-174.
9. Gash D. M., Zhang Z., Cass W. A., Ovadia A., Simmerman L., Russell D., Martin D., Collins F. C., Hoffer B. J. and Gerhardt G. A. (1995) Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. comp. Neurol. 363, 345-358.
10. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F. C., Hoffer B. J. and Gerhardt G. A. (1996) Functional recovery in GDNF-treated Parkinsonian monkeys. Nature 380, 252-255.
11. Gerfen C. R. and Young W. S. (1988) Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460, 161-167.
12. Graybiel A. (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13, 244-253.
13. Hanson G. R., Merchant K. M., Letter A. A., Bush L. and Gibb J. W. (1988) Characterization of methamphetamine effects on the striatal-nigral dynorphin system. Eur. J. Pharmac. 155, 11-18.
14. Hoffer B. J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L. F. H. and Gerhardt G. A. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182, 107-111.
15. Hudson J., Granholm A. C., Gerhardt G. A., Henry M. A., Hoffman A., Biddle P., Leela N. S., Mackerlova L., Lile J. D., Collins F. and Hoffer B. J. (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36, 425-432.
16. Jiang H. K., McGinty J. F. and Hong J. S. (1990) Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res. 507, 57-64.
17. Kearns C. and Gash D. (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672, 104-111.
18. Lapchak P. A. and Hefti F. (1992) BDNF and NGF treatment of lesioned rats: effect on cholinergic function and weight gain. NeuroReport 3, 405-408.
19. Lapchak P. A., Beck K. D., Araujo D. M., Irwin I., Langston J. W. and Hefti F. (1993) Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience 53, 639-650.
20. Lapchak P. A. and Araujo D. M. (1993) Interleukin-2 regulates monoamine and opioid peptide release from the hypothalamus. NeuroReport 4, 303-306.
21. Lapchak P. A. and Araujo D. M. (1994) NGF suppression of weight gain in adult female rats correlates with decreased hypothalamic cholecystokinin levels. Brain Res. 655, 12-16.
22. Lapchak P. A., Jiao S. S., Miller P. J., Williams L. R., Cummins V., Inouye G., Matheson C. R. and and Yan Q. (1996) Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule to treat neurodegenerative diseases. Cell Tiss. Res. 286, 179-189.
23. 125I-GDNF in the rat and primate CNS following an i.c.v. injection: correlation with the behavioral and pharmacological activities of i.c.v. administered GDNF in Parkinson's disease models. American Society for Neurotransplantation P52.
24. Lapchak P. A., Araujo D. M., Gash D. M., Hilt D. and Hoffer B. J and Collins F. (1997) Glial cell line-derived neurotrophic factor (GDNF): pharmacological activities and application to the treatment of Parkinson's disease. Expl Neurol. (in press).
25. Lapchak P. A. and Miller P. J. and Jiao S. (1996) Glial cell line-derived neurotrophic factor (GDNF) induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged F344 rats. Neuroscience (in press).
26. Lapchak P. A. (1996) Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev. Neurosci. 7, 165-176.
27. Lapchak P. A., Miller P. J., Jiao S., Araujo D. M. and Hilt D. and Collins F. (1996) Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 5, 197-205.
28. Levy R., Vial M., Herrero M. -T., Faucheux B., Agid Y. and Hirsch E. C. (1995) Striatal expression of substance P and methionin-enkephalin genes in patients with Parkinson's disease. Neurosci. Lett. 199, 22-224.
29. Lin L. -F., Doherty D. H., Lue J. D., Bektesh S. and Collins F. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 260, 1130-1132.
30. Martin D., Miller G., Fischer N., Dix D. and and Cullen T. (1996) Glial cell-line derived neurotrophic factor: the lateral cerebral ventricle is an effective site of administration for stimulation of the nigrostriatal system. Eur. J. Neurosci (in press).
31. Nisbet A. P., Foster O. J. F., Kinsgbury A., Eve D. J., Daniel S. E., Marsden C. D. and Lees A. J. (1995) Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66, 361-376.
32. Nisenbaum L. K., Kitai S. T. and Gerfen C. R. (1994) Dopaminergic and muscarinic regulation of striatal enkephalin and substance P messenger RNAs following striatal dopamine denervation: effects of systemic and central administration of quinpirole and scopolamine. Neuroscience 63, 435-449.
33. 3H]tyrosine by charcoal. Life Sci. 39, 2185-2189.
34. Robertson H. A. (1992) Synergistic interactions of D1-and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias. Can. J. neurol. Sci. 19, 147-152.
35. Robertson H. A. (1992) Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci. 15, 201-206.
36. Robertson G. S. and Robertson H. A. (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 9, 3326-3331.
37. Sauer H., Campbell K., Wiegand S. J., Lindsay R. M. and Bjorklund A. (1994) Brain-derived neurotrophic factor enhances striatal neuropeptide expression in both the intact and the dopamine-depleted rat striatum. NeuroReport 5, 609-612.
38. Waters C. M., Peck R., Rossor M., Reynolds G. P. and Hunt S. P. (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 25, 419-438.
39. Williams L. R., Inouye G., Cummins V. and Pelleymounter M. A. (1996) Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmac. exp. Ther. 277, 1140-1151.
40. Xu M., Moratalla R., Gold L. H., Hiroi N., Koob G. F., Graybiel A. M. and Tonegawa S. (1994) Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral response. Cell 79, 729-742.
41. Zech M. and Bogerts B. (1985) Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients and schizophrenics. A quantitative immunohistochemical study. Acta neuropath., Berlin 68, 32-38.